NCT01236443

Study of Photodynamic Therapy (PDT) Using HPPH in Barrett's Esophagus

A Phase I/II Study of Photodynamic Therapy (PDT) Using 2-[1-hexyloxyethyl]-2-devinylpyropheophorbide-a (HPPH) for the Treatment of High Grade Dysplasia, Carcinoma-in-situ and Early Adenocarcinoma in Barrett's Esophagus

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: Roswell Park Cancer Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A Study to identify toxicity and optimal photodynamic treatment parameters using the photosensitizer 2-\[1-hydroxyethyl\]-2-devinylpyropheophorbide-a (HPPH) in high grade dysplasia, carcinoma-in-situ, or early adenocarcinoma in Barrett's esophagus.

Conditions

• Barrett's Esophagus
• CIS
• High Grade Dysplasia

Interventions

Type	Name	Description
DRUG	HPPH	3 mg/m2 IV

Timeline

• Start date: 2000-08-01
• Primary completion: 2003-05-01
• Completion: 2013-04-01
• First posted: 2010-11-08
• Last updated: 2014-01-13

Locations

1 site across 1 country: United States